Study the Effect of Sulforaphane on the Expression of CXCR4 and Snail in Breast Cancer Cells
Authors
- Mehdi Bagheri1 1- Imam Hossein Center for Education, Research and Treatment, Shahroud University of Medical Sciences, Shahroud, Iran.
- Mozhgan Fazli2 2- School of Medicine, Shahroud University of Medical Sciences, Shahroud, Iran.
-
Naghmeh Ahmadiankia2,3
3- Cancer Prevention Research Center, Shahroud University of Medical Sciences, Shahroud, Iran.
http://orcid.org/0000-0001-8309-4935
DOI:
https://doi.org/10.22100/jkh.v13i3.1953Keywords:
Sulforaphane, Breast cancer, Metastasis, CXCR4، snailAbstract
Introduction: Metastasis is known to be the primary cause of death in the majority of breast cancer patients. The transcription factor of snail and the signaling pathway of CXCR4/SDF1are one of the most important factors in the process of metastasis. Thus, targeting EMT and CXCR4/SDF1 pathway represents an important therapeutic strategy for preventing or treating breast cancer metastasis. Natural products due to their therapeutic activities constitute a common alternative for conventional treatments. Sulforaphane (SFN), an isothiocyanate found in cruciferous vegetables, exhibits anticancer properties. Accordingly, the aim of this study was to evaluate the effects of various concentrations of SFN on cell migration in breast cancer cells and also the expression of CXCR4 and snail which are important in EMT induction and metastasis.
Methods: MDA-MB-231 cells were treated with different concentrations of SFN. The effect of SFN on cell migration was evaluated using scratch assay, after 72 hours. Next, the effect of SFN on the expression of CXCR4 and snail were examined by real-time PCR.
Results: SFN significantly retarded the migration of MDA-MB-231 cells. High concentrations of SFN (40µM), reduced the expression of CXCR4; however, There was no significant changes in the expression of snail in none of studied concentrations.
Conclusion: According to the obtained results, SFN can be considered as a potential therapeutic agent to decrease breast cancer metastasis.
References
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86. doi:10.1002/ijc.29210
DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin 2014;64:52-62. doi:10.3322/caac.21203
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90. doi:10.3322/caac.20107
Tevaarwerk AJ, Gray RJ, Schneider BP, Smith ML, Wagner LI, Fetting JH, et al. Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years. Cancer 2013;119:1140-8. doi:10.1002/cncr.27819
Chakrabarti R1, Hwang J, Andres Blanco M, Wei Y, Lukačišin M, Romano RA, et al. Elf5 inhibits the epithelial–mesenchymal transition in mammary gland development and breast cancer metastasis by transcriptionally repressing Snail2. Nat Cell Biol 2012;14:1212-22. doi:10.1038/ncb2607
Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002;2:563-72. doi:10.1038/nrc865
Xu C, Zhao H, Chen H, Yao Q. CXCR4 in breast cancer: oncogenic role and therapeutic targeting. Drug Des Devel Ther 2015;9:4953-64. doi:10.2147/DDDT.S84932
Salvucci O, Yao L, Villalba S, Sajewicz A, Pittaluga S, Tosato G. Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1. Blood 2002;99:2703-11.
Dewan MZ, Ahmed S, Iwasaki Y, Ohba K, Toi M, Yamamoto N. Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer. Biomed Pharmacother 2006;60:273-6. doi:10.1016/j.biopha.2006.06.004
Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-6. doi:10.1038/35065016
Radisky DC. Epithelial-mesenchymal transition. J Cell Sci 2005;118:4325-6. doi:10.1242/jcs.02552
Thiery JP. Epithelial–mesenchymal transitions in tumour progression. Nat Rev Cancer 2002;2:442-54. doi:10.1038/nrc822
Blanco MJ, Moreno-Bueno G, Sarrio D, Locascio A, Cano A, Palacios J, et al. Correlation of Snail expression with histological grade and lymph node status in breast carcinomas. Oncogene 2002;21:3241-6. doi:10.1038/sj.onc.1205416
Darash-Yahana M, Pikarsky E, Abramovitch R, Zeira E, Pal B, Karplus R, et al. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J 2004;18:1240-2. doi:10.1096/fj.03-0935fje
Olmeda D, Jorda M, Peinado H, Fabra A, Cano A. Snail silencing effectively suppresses tumour growth and invasiveness. Oncogene 2007;26:1862-74. doi:10.1038/sj.onc.1209997
Coseri S. Natural products and their analogues as efficient anticancer drugs. Mini Rev Med Chem 2009;9:560-71.
Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009;136:823-37. doi:10.1016/j.cell.2009.02.024
Kensler TW, Egner PA, Agyeman AS, Visvanathan K, Groopman JD, Chen JG, et al. Keap1-nrf2 signaling: a target for cancer prevention by sulforaphane. Top Curr Chem 2013;329:163-77. doi:10.1007/128_2012_339
Lenzi M, Fimognari C, Hrelia P. Sulforaphane as a promising molecule for fighting cancer. Cancer Treat Res 2014;159:207-23. doi:10.1007/978-3-642-38007-5_12
Di Pasqua AJ, Hong C, Wu MY, McCracken E, Wang X, Mi L, et al. Sensitization of non-small cell lung cancer cells to cisplatin by naturally occurring isothiocyanates. Chem Res Toxicol 2010;23:1307-9. doi:10.1021/tx100187f
Vyas AR, Singh SV. Functional relevance of D, L-sulforaphane-mediated induction of vimentin and plasminogen activator inhibitor-1 in human prostate cancer cells. Eur J Nutr 2014;53:843-52. doi:10.1007/s00394-013-0588-5
Tang L, Zirpoli GR, Guru K, Moysich KB, Zhang Y, Ambrosone CB, et al. Consumption of raw cruciferous vegetables is inversely associated with bladder cancer risk. Cancer Epidemiol Biomarkers Prev 2008;17:938-44. doi:10.1158/1055-9965.EPI-07-2502
Li W, Khor TO, Xu C, Shen G, Jeong WS, Yu S, et al. Activation of Nrf2-antioxidant signaling attenuates NFκB-inflammatory response and elicits apoptosis. Biochem Pharmacol 2008;76:1485-9. doi:10.1016/j.bcp.2008.07.017
Kensler TW, Egner PA, Agyeman AS, Visvanathan K, Groopman JD, Chen JG, et al. Keap1–nrf2 signaling: a target for cancer prevention by sulforaphane. Top Curr Chem 2013;329:163-77. doi:10.1007/128_2012_339
Wang L, Tian Z, Yang Q, Li H, Guan H, Shi B, et al. Sulforaphane inhibits thyroid cancer cell growth and invasiveness through the reactive oxygen species-dependent pathway. Oncotarget 2015;6:25917-31. doi:10.18632/oncotarget.4542
Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004;4:540-50. doi:10.1038/nrc1388
Kim B, Park B. Baohuoside I suppresses invasion of cervical and breast cancer cells through the downregulation of CXCR4 chemokine receptor expression. Biochemistry 2014;53:7562-9. doi:10.1021/bi5011927
Chen XP, Qian LL, Jiang H, Chen JH. Ginsenoside Rg3 inhibits CXCR 4 expression and related migrations in a breast cancer cell line. Int J Clin Oncol 2011;16:519-23. doi:10.1007/s10147-011-0222-6
Hirbe AC, Morgan EA, Weilbaecher KN. The CXCR4/SDF-1 chemokine axis: a potential therapeutic target for bone metastases? Curr Pharm Des 2010;16:1284-90.
Hu CT, Wu JR, Chang TY, Cheng CC, Wu WS. The transcriptional factor Snail simultaneously triggers cell cycle arrest and migration of human hepatoma HepG2. J Biomed Sci 2008;15:343-55. doi:10.1007/s11373-007-9230-y
Chen J, Chang H, Peng X, Gu Y, Yi L, Zhang Q, et al. 3, 6-dihydroxyflavone suppresses the epithelial-mesenchymal transition in breast cancer cells by inhibiting the Notch signaling pathway. Sci Rep 2016;6:28858. doi:10.1038/srep28858
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
